Results 1 to 10 of about 328,224 (217)

Metabolic syndrome and immune-related adverse events [PDF]

Cancer Immunology, Immunotherapy
Background Years into the immune checkpoint inhibitor (ICI) era, immune-related adverse events (irAE) remain largely unpredictable. Prior studies have examined irAE associations with weight and metabolic diseases, yielding mixed findings.
Katherine Lei, Meera J. Patel, Jialiang Liu, Rutu Aniruddha Rathod, Mitchell S. von Itzstein, Farjana J. Fattah, Hong Mu-Mosley, Jeffrey A. SoRelle, Jason Y. Park, Yang Xie, Amy E. Hughes, Heather Kitzman, David E. Gerber   +12 more
doaj   +2 more sources

Correction: Metabolic syndrome and immune-related adverse events [PDF]

Cancer Immunology, Immunotherapy
Katherine Lei, Meera J. Patel, Jialiang Liu, Rutu Aniruddha Rathod, Mitchell S. von Itzstein, Farjana J. Fattah, Hong Mu-Mosley, Jeffrey A. SoRelle, Jason Y. Park, Yang Xie, Amy E. Hughes, Heather Kitzman, David E. Gerber   +12 more
doaj   +2 more sources

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events

Pharmaceuticals, 2023
Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform/lichenoid ircAE phenotype.
Stephanie L. Gu, Tara Maier, Andrea P. Moy, Stephen Dusza, David M. Faleck, Neil J. Shah, Mario E. Lacouture   +6 more
doaj   +1 more source

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations

OncoImmunology, 2023
Immune-related adverse events (irAEs) are side effects of immune checkpoint inhibitor therapy (ICI). While common irAEs have been well characterized, there are more limited data on rare immune related adverse events (RirAEs) due to low incidence. Lack of
Benjamin C. Park, Sathya Narayanan, Alexander Gavralidis, Fei Ye, Run Fan, Ryan J. Sullivan, Genevieve Boland, Kerry L Reynolds, Justin M. Balko, Matteo S. Carlino, Georgina V. Long, Leyre Zubiri, Alexander M. Menzies, Douglas B. Johnson   +13 more
doaj   +1 more source

Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review

Frontiers in Oncology, 2021
BackgroundImmune Checkpoint Inhibitors (ICI) have been progressively used in cancer treatment and produced unique toxicity profiles. This systematic review aims to comprehend the patterns and occurrence of treatment-related adverse events (trAEs) based ...
Tao Ouyang, Tao Ouyang, Yanyan Cao, Yanyan Cao, Xuefeng Kan, Xuefeng Kan, Lei Chen, Lei Chen, Yanqiao Ren, Yanqiao Ren, Tao Sun, Tao Sun, Liangliang Yan, Liangliang Yan, Bin Xiong, Bin Xiong, Bin Liang, Bin Liang, Chuansheng Zheng, Chuansheng Zheng   +19 more
doaj   +1 more source

Rheumatological Adverse Events Following Immunotherapy for Cancer

Medicina, 2022
Background and Objectives: The occurrence of rheumatological side effects in a patient after receiving immunotherapy for cancer is becoming increasingly common. Oncologists often fail to diagnose and refer affected patients to rheumatologists. This paper
Ioana Cretu, Bogdan Cretu, Catalin Cirstoiu, Adrian Cursaru, Mihaela Milicescu, Mihai Bojinca, Ruxandra Ionescu   +6 more
doaj   +1 more source

Gastrointestinal disorders as immune-related adverse events

Exploration of Targeted Anti-tumor Therapy, 2021
Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer therapy.
Daniele Balducci, Claudia Quatraccioni, Antonio Benedetti, Marco Marzioni, Luca Maroni   +4 more
doaj   +1 more source

Immune-related adverse events: A bibliometric analysis

Frontiers in Immunology, 2022
BackgroundDespite providing clinical benefit, immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) in a number of patients.
Shi-Tao Jiang, Yao-Ge Liu, Lei Zhang, Xin-Ting Sang, Yi-Yao Xu, Xin Lu   +5 more
doaj   +1 more source

Immune checkpoint inhibitors⁃related nervous system adverse events

Chinese Journal of Contemporary Neurology and Neurosurgery, 2022
Immune checkpoint inhibitors (ICIs) have been widely used in tumor treatment. Immune⁃related adverse events (irAEs) are common in skin, endocrine, gastrointestinal tract, liver and cardiovascular system symptoms.
WANG Ze⁃yi, LIU Guang⁃zhi
doaj   +1 more source

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report

Frontiers in Oncology, 2020
BackgroundImmune checkpoint inhibitors targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed death-1 receptor (PD-1), and programmed death-1 receptor and its ligand (PD-L1) increased the survival of patients affected by metastatic ...
Maria Anna Siciliano, Stefano Dastoli, Stefano Dastoli, Maria d’Apolito, Nicoletta Staropoli, Pierfrancesco Tassone, Pierfrancesco Tassone, Pierosandro Tagliaferri, Pierosandro Tagliaferri, Vito Barbieri   +9 more
doaj   +1 more source